These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2083198)

  • 1. Ventricular fibrillation and torsades de pointes.
    Dessertenne F; Coumel P; Fabiato A
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1177-82. PubMed ID: 2083198
    [No Abstract]   [Full Text] [Related]  

  • 2. Ventricular Tachycardias: Characteristics and Management.
    Baldzizhar A; Manuylova E; Marchenko R; Kryvalap Y; Carey MG
    Crit Care Nurs Clin North Am; 2016 Sep; 28(3):317-29. PubMed ID: 27484660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of a short-coupled variant of torsades de Pointes with electrical storm.
    Takeuchi T; Sato N; Kawamura Y; Takahashi F; Sato M; Kikuchi K; Akasaka N; Go K; Fujimoto K; Hasebe N
    Pacing Clin Electrophysiol; 2003 Feb; 26(2 Pt 1):632-6. PubMed ID: 12710326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.
    Hoehns JD; Stanford RH; Geraets DR; Skelly KS; Lee HC; Gaul BL
    Pharmacotherapy; 2001 Jul; 21(7):871-83. PubMed ID: 11444585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes.
    Loffi M; Toffetti L; Gianni C; Lombardi F
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):811-3. PubMed ID: 25648339
    [No Abstract]   [Full Text] [Related]  

  • 7. Degenerating regenerating torsades de pointes.
    Perrin MJ; Gollob MH; Birnie DH; Nery PB; Keren A
    Pacing Clin Electrophysiol; 2013 Mar; 36(3):e80-3. PubMed ID: 22469253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial fibrillation followed by torsade de pointes degenerated into ventricular fibrillation spontaneously terminated and restored sinus rhythm.
    Santoro F; Ieva R; Ferraretti A; De Gennaro L; Di Biase M; Brunetti ND
    Int J Cardiol; 2013 Jul; 166(3):e39-40. PubMed ID: 23453872
    [No Abstract]   [Full Text] [Related]  

  • 9. Torsades de pointes and self-terminating ventricular fibrillation in a prescription methadone user.
    Atkinson D; Dunne A; Parker M
    Anaesthesia; 2007 Sep; 62(9):952-5. PubMed ID: 17697226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors of ventricular fibrillation triggered by pause-dependent torsades de pointes associated with acquired long QT interval: role of QT dispersion and left ventricular function.
    Da Costa A; Chalvidan T; Belounas A; Messier M; Viallet M; Mansour H; Lamaison D; Djiane P; Isaaz K
    J Cardiovasc Electrophysiol; 2000 Sep; 11(9):990-7. PubMed ID: 11021469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torsades de pointes: electrophysiologic studies in patients without transient pharmacologic or metabolic abnormalities.
    Horowitz LN; Greenspan AM; Spielman SR; Josephson ME
    Circulation; 1981 May; 63(5):1120-8. PubMed ID: 7471373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
    Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
    J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ventricular arrhythmias in ion channel diseases].
    Wolpert C; Vogel M; Nagel C; Herrera-Siklody C; Rüb N
    Herzschrittmacherther Elektrophysiol; 2017 Jun; 28(2):169-176. PubMed ID: 28534204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Torsades de pointes ventricular tachycardia induced by intravenous amiodarone].
    Makai A; Rudas L; Liszkai G; Fazekas T
    Orv Hetil; 2003 Feb; 144(5):241-7. PubMed ID: 12647553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of in-hospital ventricular fibrillation or torsades de pointes in patients with acute symptomatic bradycardia.
    Díaz-Castro O; Puchol A; Almendral J; Torrecilla EG; Arenal A; Martínez-Selles M
    J Electrocardiol; 2004 Jan; 37(1):55-60. PubMed ID: 15132370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Torsade de pointes.
    Munro PT; Graham CA
    Emerg Med J; 2002 Sep; 19(5):485-6. PubMed ID: 12205024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
    Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
    J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. QT interval prolongation and ventricular fibrillation in childhood end-stage renal disease.
    Kim GB; Cho HY; Kwon BS; Bae EJ; Noh CI; Choi JY; Yun YS; Choi Y; Ha JW
    Int J Cardiol; 2008 Jul; 127(3):e126-8. PubMed ID: 17714808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular tachycardia with two variable foci.
    Dessertenne F
    Cardiovasc Drugs Ther; 1990 Aug; 4(4):1171-6. PubMed ID: 2083197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.